This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know
2026-03-21 18:33:31 ET
Kynam Capital Management trimmed its stake in Viridian Therapeutics (NASDAQ:VRDN) , selling 2,957,386 shares in the fourth quarter, an estimated $81.11 million transaction based on quarterly average pricing, according to a February 17, 2026, SEC filing.
According to a filing with the U.S. Securities and Exchange Commission dated February 17, 2026, Kynam Capital Management reduced its holding in Viridian Therapeutics by 2,957,386 shares during the fourth quarter. The estimated transaction value is $81.11 million, calculated using the average closing price for the quarter. The value of the Viridian stake at quarter-end declined by $49.79 million, a figure that includes both trading and market price effects.
Viridian Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the development of innovative antibody-based therapies for serious diseases. With a pipeline led by candidates targeting thyroid eye disease, the company leverages advanced monoclonal antibody technology to address unmet medical needs. Viridian’s strategy is rooted in scientific expertise and a focus on high-value specialty markets, positioning it to compete in the evolving biotechnology sector.
NASDAQ: VRDN
VRDN Trading
1.6% G/L:
$27.95 Last:
586,877 Volume:
$27.62 Open:
